These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24762544)

  • 21. Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung.
    Grob TJ; Kannengiesser I; Tsourlakis MC; Atanackovic D; Koenig AM; Vashist YK; Klose H; Marx AH; Koops S; Simon R; Izbicki JR; Bokemeyer C; Sauter G; Wilczak W
    Mod Pathol; 2012 Dec; 25(12):1566-73. PubMed ID: 22899293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FGFR1 expression and gene copy numbers in human lung cancer.
    Kohler LH; Mireskandari M; Knösel T; Altendorf-Hofmann A; Kunze A; Schmidt A; Presselt N; Chen Y; Petersen I
    Virchows Arch; 2012 Jul; 461(1):49-57. PubMed ID: 22648708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new bright-field dual-colour chromogenic and silver in situ hybridization method for the detection of FGFR1 gene copy number status.
    Boehm D; Vogel W; Franzen A; Schrock A; Bootz F; Heaseley LE; Braun M; Perner S
    Virchows Arch; 2014 May; 464(5):547-51. PubMed ID: 24584974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence for frequent concurrent DCUN1D1, FGFR1, BCL9 gene copy number amplification in squamous cell lung cancer.
    Chatziandreou I; Psaraki A; Paschidis K; Lazaris AC; Saetta AA
    Pathol Res Pract; 2021 May; 221():153412. PubMed ID: 33862557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib.
    Ng TL; Yu H; Smith DE; Boyle TA; York ER; Leedy S; Gao D; Aisner DL; Van Bokhoven A; Heasley LE; Hirsch FR; Camidge DR
    Clin Lung Cancer; 2019 Jan; 20(1):e39-e51. PubMed ID: 30297175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer.
    Seo AN; Jin Y; Lee HJ; Sun PL; Kim H; Jheon S; Kim K; Lee CT; Chung JH
    Virchows Arch; 2014 Nov; 465(5):547-58. PubMed ID: 25086725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer.
    Park JS; Lee JS; Kim EY; Jung JY; Kim SK; Chang J; Kim DJ; Lee CY; Jung I; Kim JH; Kim HR; Moon YW; Kim HS; Cho BC; Shim HS
    Lung Cancer; 2015 Jun; 88(3):325-31. PubMed ID: 25819384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer.
    Zhang L; Yu H; Badzio A; Boyle TA; Schildhaus HU; Lu X; Dziadziuszko R; Jassem J; Varella-Garcia M; Heasley LE; Kowalewski AA; Ellison K; Chen G; Zhou C; Hirsch FR
    J Thorac Oncol; 2015 Jul; 10(7):1083-90. PubMed ID: 26020126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung.
    Usul Afsar C; Sahin B; Gunaldi M; Kılıc Bagir E; Gumurdulu D; Burgut R; Erkisi M; Kara IO; Paydas S; Karaca F; Ercolak V
    Int J Clin Exp Pathol; 2015; 8(9):9760-71. PubMed ID: 26617686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibroblast growth factor receptor-1 as a potential therapeutic target in sinonasal cancer.
    Schröck A; Göke F; Wagner P; Bode M; Franzen A; Huss S; Agaimy A; Ihrler S; Kirsten R; Kristiansen G; Bootz F; Lengerke C; Perner S
    Head Neck; 2014 Sep; 36(9):1253-7. PubMed ID: 23913758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study.
    Lim SH; Sun JM; Choi YL; Kim HR; Ahn S; Lee JY; Lee SH; Ahn JS; Park K; Kim JH; Cho BC; Ahn MJ
    Cancer; 2016 Oct; 122(19):3024-31. PubMed ID: 27315356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors.
    Göke F; Franzen A; Menon R; Goltz D; Kirsten R; Boehm D; Vogel W; Göke A; Scheble V; Ellinger J; Gerigk U; Fend F; Wagner P; Schroeck A; Perner S
    Chest; 2012 Oct; 142(4):1020-1026. PubMed ID: 22499828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
    Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
    Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Silver-enhanced in situ hybridization for determination of EGFR copy number alterations in non-small cell lung cancer.
    Wulf MA; Bode B; Zimmermann D; Rufibach K; Weder W; Moch H; Soltermann A; Tischler V
    Am J Surg Pathol; 2012 Dec; 36(12):1801-8. PubMed ID: 23154768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer.
    Schultheis AM; Bos M; Schmitz K; Wilsberg L; Binot E; Wolf J; Büttner R; Schildhaus HU
    Mod Pathol; 2014 Feb; 27(2):214-21. PubMed ID: 23887299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FGFR1 is amplified during the progression of in situ to invasive breast carcinoma.
    Jang M; Kim E; Choi Y; Lee H; Kim Y; Kim J; Kang E; Kim SW; Kim I; Park S
    Breast Cancer Res; 2012 Aug; 14(4):R115. PubMed ID: 22863309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer.
    Wilbertz T; Wagner P; Petersen K; Stiedl AC; Scheble VJ; Maier S; Reischl M; Mikut R; Altorki NK; Moch H; Fend F; Staebler A; Bass AJ; Meyerson M; Rubin MA; Soltermann A; Lengerke C; Perner S
    Mod Pathol; 2011 Jul; 24(7):944-53. PubMed ID: 21460799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fibroblast growth factor receptor 1 amplification in non-small cell lung cancer by quantitative real-time PCR.
    Gadgeel SM; Chen W; Cote ML; Bollig-Fischer A; Land S; Schwartz AG; Bepler G
    PLoS One; 2013; 8(11):e79820. PubMed ID: 24255716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
    Francis GD; Jones MA; Beadle GF; Stein SR
    Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.